New obesity shot enters first human safety tests

NCT ID NCT07624071

Recruiting now Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 7 times

Summary

This early-stage trial tests a new drug called ALN-6222 in 88 adults with obesity (BMI 30-40). Participants receive a single injection of either the drug or a placebo. The main goal is to check safety and how the body processes the drug, not weight loss. It is the first time this drug is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALN-6222
What this could lead to: If successful, this could lead to a new injectable treatment for obesity that helps control weight.
What could go wrong: This is a very early Phase 1 study with only 88 people. It primarily checks safety, not weight loss. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Clinical Trial Site
RECRUITING

Mount Royal, H3P 3P1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.